A young and accomplished investor and company advisor, Jack actively works with a select set of entrepreneurs to help pursue their mission of revolutionizing patient care. He manages his entrepreneurial activities, including forming and running new ventures, investing, and advising companies via a holding company, Breezy Point. Breezy Point’s interests span the entire universe of healthcare, including drug development, tools to accelerate drug discovery, and healthcare services.

Previously, Jack served as an Investor at Estuary Capital Management, a global, fundamentally-driven investment firm. In that role, he identified and researched ideas for public equity investments, primarily in healthcare.

Before joining Estuary, Jack started his investment career at SV Health Investors, where he focused predominantly on investments in early-stage drug development. While at SV, Jack played a significant role in the strategy of Eyebiotech Limited (acq. in 2024 for up to $3.0B), Caraway Therapeutics (acq. in 2023 for up to $610M), Rondo Therapeutics, and Catamaran Bio. Prior to SV, Jack began his career at ClearView Healthcare Partners advising pharmaceutical and biotechnology clients on corporate strategy.

Jack received an M.S. from the University of Notre Dame and an A.B. from the College of the Holy Cross, where he was a double major in Chemistry and Economics and served on the Men’s Varsity Ice Hockey team. He lives in Deephaven, Minnesota with his wife, Emily. Jack is a cancer survivor and cares deeply about the advancement of new treatments to improve cancer care globally.